GlassScriptPhysician profile
William S Kamanda
NPI 1275597650
$11,559.98
in general payments reported to CMS, 2019-2025
56 companies · $1,200 in 2025
The $1,200 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $644 · 2020: $565 · 2021: $1,127 · 2022: $1,130 · 2023: $1,895 · 2024: $4,999 · 2025: $1,200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,812 · Consulting Fee: $2,910 · Long Term Medical Supply Or Device Loan: $781 · Travel and Lodging: $346 · Education: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,812.35 |
| Consulting Fee | $2,910.00 |
| Long Term Medical Supply Or Device Loan | $781.23 |
| Travel and Lodging | $345.88 |
| Education | $243.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,953.11 | 2019-2025 | Imfinzi, Enhertu |
| Novartis Pharmaceuticals Corporation | $1,748.29 | 2019-2025 | |
| Daiichi Sankyo INC. | $762.49 | 2019-2024 | Enhertu, Enhertu, Injectafer |
| Janssen Biotech, INC. | $708.10 | 2019-2024 | Erleada, Akeega, Balversa |
| Pharmacyclics LLC, An Abbvie Company | $329.54 | 2021-2023 | Imbruvica, Epkinly |
| Exelixis INC. | $315.57 | 2019-2025 | Cabometyx |
| Kyowa Kirin, INC. | $299.78 | 2019-2023 | Poteligeo |
| Astellas Pharma US INC | $295.29 | 2020-2024 | Xtandi |
| Incyte Corporation | $215.91 | 2021-2025 | Monjuvi, Jakafi, Zynyz |
| Amgen INC. | $210.62 | 2019-2023 | Lumakras, Kyprolis |
| Regeneron Healthcare Solutions, INC. | $207.77 | 2021-2025 | Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.22 | 2020-2022 | |
| Pfizer INC. | $194.40 | 2020-2024 | |
| Pharmaessentia USA Corporation | $193.69 | 2023-2025 | Besremi |
| Genzyme Corporation | $191.16 | 2019-2025 |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $188.58 | 2019-2025 | Reblozyl, Opdualag, Opdivo |
| E.R. Squibb & Sons, L.L.C. | $188.04 | 2019-2024 | Opdivo, Opdualag |
| Abbvie INC. | $166.74 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $151.08 | 2025 | Onivyde |
| Blueprint Medicines Corporation | $148.50 | 2022-2025 | Ayvakit |
| Seagen INC. | $140.38 | 2019-2023 | Adcetris, Tukysa |
| Foundation Medicine, INC. | $139.10 | 2023 | Foundationone Cdx, Foundationone Liquid Cdx |
| Merck Sharp & Dohme LLC | $132.28 | 2021-2024 | Keytruda, Lynparza, Welireg |
| Pharmacosmos Therapeutics INC. | $123.45 | 2021-2025 | Monoferric |
| Dendreon Pharmaceuticals LLC | $115.54 | 2023-2024 | Provenge |
| Tersera Therapeutics LLC | $112.07 | 2023-2025 | Zoladex |
| Eisai INC. | $83.83 | 2020-2025 | |
| Stemline Therapeutics INC. | $81.19 | 2023-2025 | Orserdu |
| Emd Serono, INC. | $78.65 | 2021-2025 | |
| Glaxosmithkline, LLC. | $72.68 | 2022-2025 | Zejula, Ojjaara |
| Gilead Sciences, INC. | $61.48 | 2021-2025 | Trodelvy |
| Myovant Sciences INC. | $56.68 | 2022 | |
| Genentech USA, INC. | $55.58 | 2019-2023 | Rozlytrek, Gavreto, Alecensa |
| Lilly USA, LLC | $55.20 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Adaptive Biotechnologies Corporation | $48.00 | 2025 | Clonoseq |
| Mylan Institutional INC. | $45.68 | 2019 | |
| Sumitomo Pharma America, INC. | $44.42 | 2024-2025 | Orgovyx |
| Sobi, INC | $41.84 | 2023-2025 | |
| Array Biopharma INC | $36.69 | 2023 | Xalkori, Lorbrena, Braftovi |
| Cti Biopharma Corp. | $32.14 | 2023 | Vonjo |
| Janssen Pharmaceuticals, INC | $30.63 | 2019 | |
| Aveo Pharmaceuticals, INC. | $30.60 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.30 | 2024 | |
| Puma Biotechnology, INC. | $23.70 | 2025 | |
| Telix Pharmaceuticals | $23.17 | 2024 | Illuccix |
| Karyopharm Therapeutics INC. | $22.50 | 2025 | Xpovio |
| Immunocore Limited | $21.33 | 2025 | Kimmtrak |
| Rigel Pharmaceuticals, INC. | $21.15 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Lexicon Pharmaceuticals, INC. | $21.04 | 2020 | |
| Taiho Oncology, INC. | $20.82 | 2023 | |
| Agios Pharmaceuticals, INC. | $19.70 | 2025 | Pyrukynd |
| Spectrum Pharmaceuticals INC. | $19.44 | 2025 | Rolvedon |
| Springworks Therapeutics, INC. | $16.77 | 2025 | Gomekli |
| Upsher-Smith Laboratories LLC | $15.80 | 2021 | |
| Medtronic, INC. | $14.94 | 2022 | |
| Clovis Oncology, INC. | $10.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Kamanda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.